Optic Neuritis News and Research

RSS

Optic neuritis is a condition in which the optic nerve becomes inflamed and swollen, leading to an acute severe impairment of vision in the affected eye. The swelling may further lead to damage to the nerve fibers running through the nerve, causing permanent or temporary loss of vision in that eye. It is much more common in young female patients.

OCT imaging method can improve diagnosis of multiple sclerosis

A study conducted by researchers from the Department of Neurology at MedUni Vienna and University Hospital Vienna has demonstrated for the first time that diagnosis of multiple sclerosis (MS) can be significantly improved by additionally measuring the thickness of retinal layers in the eye.

6 Jul 2023

New insights into how axons grow could lead to effective therapies for blindness, paralysis

Injuries to the nerves can blind or paralyze because adult nerve cells don't regenerate their connections. Now, a team of UConn School of Medicine researchers report in Development that at least a small population of nerve cells exist in everyone that could be coaxed to regrow, potentially restoring sight and movement.

31 May 2023

Study uncovers new prognostic marker for multiple sclerosis severity

It is essential to assess the severity of multiple sclerosis (MS) in order to choose appropriate therapeutic measures, but this cannot be reliably done using existing methods.

10 Aug 2022

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

A new study reported four cases of Myelin Oligodendrocyte Glycoprotein-Associated Disorder that commenced after SARS-CoV-2 infection.

21 Jun 2022

Study explores neurologic complications in pediatric COVID-19 cases

Researchers evaluated neurologic complications in pediatric cases of COVID-19.

18 May 2022

Researchers develop a classification scheme for neuromyelitis optica spectrum disorder

Researchers in the Department of Neurology at Tohoku University, which is led by professor Masashi Aoki, have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare autoimmune disease that until recently was thought to be a type of multiple sclerosis (MS).

15 Apr 2021

New technology can help develop diagnostic tests for multiple sclerosis

Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting more than 2 million individuals worldwide, with about 1500 cases in Estonia. About 20% of MS patients experience optic neuritis (ON) as the presenting symptom, but not all ON patients develop MS.

12 Feb 2021

Remyelinating drug shows potential to improve vision in patients with MS

A team led by a biomedical scientist at the University of California, Riverside, reports a drug -- an estrogen receptor ligand called indazole chloride (IndCl) -- has the potential to improve vision in patients with multiple sclerosis, or MS.

2 Feb 2021

Home-based pediatric teleneuropsychology evaluations shown to be effective

Administering neuropsychology evaluations to children online in the comfort of their own homes is feasible and delivers results comparable to tests traditionally performed in a clinic, a new study led by UT Southwestern researchers and Children's Health indicates.

24 Sep 2020

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who are anti-aquaporin-4 or AQP4 antibody-positive.

17 Aug 2020

Study: Certain inflammatory demyelinating diseases belong to different category than multiple sclerosis

An antibody appears to make a big difference between multiple sclerosis and other disorders affecting the protective myelin sheath around nerve fibers, report Tohoku University scientists and colleagues in the journal Brain.

19 May 2020

Researchers find possible causes for lacking of effective therapy for multiple sclerosis

Medications currently used to treat multiple sclerosis can merely reduce relapses during the initial relapsing-remitting phase.

20 Aug 2019

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.

27 Jun 2019

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Popular allergy drug may reduce relapses in patients with neuromyelitis optica

The addition of cetirizine (the popular allergy medication sold under the brand name Zyrtec) to standard therapy is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis optica (NMO), a rare and severe disease that causes inflammation and demyelination (damage to the myelin - the protective coating of nerve cells), primarily in the optic nerve (optic neuritis), spinal cord (myelitis), and brainstem.

2 Feb 2018

Updated ‘McDonald Criteria’ expected to improve speed and accuracy of MS diagnosis

The McDonald Criteria for the Diagnosis of Multiple Sclerosis have just been revised by a 30-member international panel of MS experts co-chaired by Jeffrey Cohen, MD (Cleveland Clinic) and Alan Thompson, MD (University College London).

22 Dec 2017

Mayo Clinic launches new clinical test that distinguishes IDDs from multiple sclerosis

Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder.

28 Nov 2017

New therapeutic agent shows potential for treating optic neuritis linked to multiple sclerosis

A new therapeutic agent tested in a mouse model of multiple sclerosis (MS) produced anti-inflammatory activity and prevented loss of cells in the optic nerve, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania, with Pittsburgh-based Noveome Biotherapeutics.

9 Feb 2017

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Color-deficiency or color-blindness?

Color blindness could be considered a bit of a misleading term, because there are very few people who can't see color at all. Most people have what we call color deficiency or color confusion, which means that they're not blind to color; they just see a reduced number of colors.

From Vision Express 22 Sep 2016